MiMedx Group Inc
NASDAQ:MDXG

Watchlist Manager
MiMedx Group Inc Logo
MiMedx Group Inc
NASDAQ:MDXG
Watchlist
Price: 9.2 USD -0.22% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
MiMedx Group Inc?
Write Note

MiMedx Group Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

MiMedx Group Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
MiMedx Group Inc
NASDAQ:MDXG
Revenue
$342.8m
CAGR 3-Years
10%
CAGR 5-Years
2%
CAGR 10-Years
13%
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

MiMedx Group Inc
Revenue Breakdown

Breakdown by Geography
MiMedx Group Inc

Not Available

Breakdown by Segments
MiMedx Group Inc

Total Revenue: 321.5m USD
100%
Hospital: 187m USD
58.2%
Private Office: 95.8m USD
29.8%
Other: 38.7m USD
12%

MiMedx Group Inc
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 811 full-time employees. The company went IPO on 2007-08-20. The firm is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company’s primary platform technologies include EPIFIX, AMNIOFIX, EPICORD, and AMNIOCORD. The AMNIOFIX and EPIFIX are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. Its EPICORD and AMNIOCORD are tissue allografts derived from umbilical cord tissue. EPIFIX is a semi-permeable, protective barrier allograft comprised of dehydrated human amnion/chorion membrane that may be used in the treatment of chronic wounds, including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers. AMNIOFIX is used in surgical recovery applications including in the areas of spine, orthopedic, sports medicine and urologic.

MDXG Intrinsic Value
6.5 USD
Overvaluation 29%
Intrinsic Value
Price

See Also

What is MiMedx Group Inc's Revenue?
Revenue
342.8m USD

Based on the financial report for Sep 30, 2024, MiMedx Group Inc's Revenue amounts to 342.8m USD.

What is MiMedx Group Inc's Revenue growth rate?
Revenue CAGR 10Y
13%

Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for MiMedx Group Inc have been 10% over the past three years , 2% over the past five years , and 13% over the past ten years .

Back to Top